摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

perhydro-3a,5a,8a,11a-tetraazacyclohepta[d,e,f]phenanthrene | 74199-13-6

中文名称
——
中文别名
——
英文名称
perhydro-3a,5a,8a,11a-tetraazacyclohepta[d,e,f]phenanthrene
英文别名
homocyclam glyoxal;(16R,17S)-1,5,9,12-tetrazatetracyclo[7.6.2.05,17.012,16]heptadecane
perhydro-3a,5a,8a,11a-tetraazacyclohepta[d,e,f]phenanthrene化学式
CAS
74199-13-6
化学式
C13H24N4
mdl
——
分子量
236.36
InChiKey
ZAVOUJVICUCFTO-BETUJISGSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    17
  • 可旋转键数:
    0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    13
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    perhydro-3a,5a,8a,11a-tetraazacyclohepta[d,e,f]phenanthrene一水合肼 作用下, 以 乙腈 为溶剂, 反应 168.0h, 生成 1-[4-(1,4,8,12-tetraazacyclopentadecan-1-ylmethyl)benzyl]-1,4,8,12-tetraazacyclopentadecane
    参考文献:
    名称:
    双缩醛:双大环合成的有效工具
    摘要:
    四氮杂大环双缩醛被证明是合成对称,不对称或功能化的双四氮杂大环的极好工具。该方法的关键特征是分离不溶的单或双季铵盐铵盐 在烷基化反应过程中从溶液中分离。
    DOI:
    10.1039/b103995b
  • 作为产物:
    描述:
    1,4,8,12-四氮杂环十五烷草酸醛甲醇 为溶剂, 反应 3.0h, 以90%的产率得到perhydro-3a,5a,8a,11a-tetraazacyclohepta[d,e,f]phenanthrene
    参考文献:
    名称:
    双缩醛:双大环合成的有效工具
    摘要:
    四氮杂大环双缩醛被证明是合成对称,不对称或功能化的双四氮杂大环的极好工具。该方法的关键特征是分离不溶的单或双季铵盐铵盐 在烷基化反应过程中从溶液中分离。
    DOI:
    10.1039/b103995b
点击查看最新优质反应信息

文献信息

  • Probing the Limits of Tetraazamacrocycle‐Glyoxal Condensates as Bidentate Ligands for Cu <sup>2+</sup>
    作者:Paul D. Won、Neil L. Funwie、Orry C. Birdsong、Aslihan Yilmaz Obali、Benjamin P. Burke、Graeme McRobbie、Peter Greenman、Timothy J. Prior、Stephen J. Archibald、Timothy J. Hubin
    DOI:10.1002/ejic.201500683
    日期:2015.10
    Tetracyclic bisaminals formed by condensation of tetraazamacrocycles and glyoxal have rarely been utilized as ligands for transition metal ions. Five novel Cu2+ complexes are presented to expand this set. Glyoxal derivatives of pyruvic aldehyde and butanedione were expected to further rigidify the bisaminal skeleton because of the steric requirements of the methyl groups, while the previously unutilized
    由四氮杂大环和乙二醛缩合形成的四环双胺很少被用作过渡金属离子的配体。提出了五种新颖的 Cu2+ 配合物来扩展该集合。由于甲基的空间要求,预计丙酮醛和丁二酮的乙二醛衍生物将进一步硬化双胺骨架,而由于七元环的存在,预计以前未使用的同环戊烷会增加柔韧性。此外,还制备了一种硝基复合物,以检查体积更大的单齿配体对双胺骨架的影响。新配合物显示出类似的 Cu2+ 的四配位,但由于乙二醛桥被一个或两个甲基取代,配位几何结构发生了显着变化。由于较大的大环的灵活性,同环素衍生物产生了完全不同的配位模式。使用硝基代替典型的氯代单齿配体会影响结构和电子特性。总体而言,电子特性(磁矩、电子光谱和循环伏安法)仅受到轻微影响。然而,当使用较大的同环异丁烯大环或使用硝基阴离子代替氯配体来完成配位时,观察到更大的变化。此外,最近公布的几何指数 τδ 是通过使用这一系列密切相关的 Cu2+ 配合物来评估的。使用硝基代替典型的
  • Bis-aminals: efficient tools for bis-macrocycle synthesis
    作者:Michel Le Baccon、Françoise Chuburu、Loïc Toupet、Henri Handel、Mathieu Soibinet、Isabelle De′champs-Olivier、Jean-Pierre Barbier、Michel Aplincourt
    DOI:10.1039/b103995b
    日期:——
    for the synthesis of symmetrical, dissymmetrical or functionalized bis-tetraazamacrocycles. The key feature of the process is the separation of insoluble mono- or bis-quaternary ammonium salts from solution during the course of the alkylation reaction.
    四氮杂大环双缩醛被证明是合成对称,不对称或功能化的双四氮杂大环的极好工具。该方法的关键特征是分离不溶的单或双季铵盐铵盐 在烷基化反应过程中从溶液中分离。
查看更多

同类化合物

阿斯普尼辛B 阿斯普尼辛 D 阿斯普尼辛 苯佐莫文 新骏河毒素 乙酰胺,N-(4-硝基-2-吡啶基)-,氧化(9CI) TAK960抑制剂 PLK1抑制剂(RO3280) 8H-嘧啶并[4,5-b][1,4]二氮杂卓 8-甲基-5,9-二氢-6H-嘧啶并[4,5-b][1,4]重氮基庚英-6-酮 6H-嘧啶并[4,5-b][1,4]二氮杂卓 4-甲基-6,11-二氢-3H-嘧啶并[4,5-b][1,5]苯并二氮杂卓-2,5-二酮 2-氯-7,7-二氟-5-甲基-5,7,8,9-四氢-6H-嘧啶基[4,5-B][1,4]二氮杂-6-酮 2-氯-5-甲基-5,7,8,9-四氢-6H-嘧啶[4,5-B][1,4]二氮杂6-酮 1H-嘧啶并[4,5-b][1,4]二氮杂卓 4-amino-8-(1,3-benzodioxol-5-yl)-6-phenyl-8,9-dihydro-7H-pyrimido[4,5-b][1,4]diazepine 2-(2-Bromo-4-isopropyl-phenyl)-4-methyl-6-pentyl-6,7,8,9-tetrahydro-2H-2,3,5,6,9a-pentaaza-benzo[cd]azulen-1-one 2-chloro-8-(trifluoromethyl)-6H,11H-benzo[b]pyrimidino[5,4-f]-1,4-diazaperhydroepin-5-one 4,5,6,7-tetrahydro-2,4-diphenyl-4,7a,12b-triazadibenzo[e,g]azulene-1,3,8-trione 4,5,6,7-tetrahydro-4-methyl-2-phenyl-4,7a,12b-triazadibenzo[e,g]azulene-1,3,8-trione N-(4-((8,9-dimethoxy-5-methyl-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-11H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-5-methyl-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-fluorophenyl)-N-(4-((8-methoxy-2-methyl-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-fluorophenyl)-N-(4-((8-methoxy-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-11H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide di-tert-butyl (1r,4r)-4-(4-(9-cyclohexyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxybenzamido)cyclohexyl phosphate 2-(2-Bromo-4-isopropyl-phenyl)-6-(1-ethyl-propyl)-4-methyl-6,7,8,9-tetrahydro-2H-2,3,5,6,9a-pentaaza-benzo[cd]azulen-1-one 7,8,9,10-tetrahydro-10-hydroxy-9-heptyl-[1,4]diazepino[1,2,3-g,h]purine 7,8,9,10-tetrahydro-10-hydroxy-9-methyl-9-propyl[1,4]diazepino[1,2,3-g,h]purine 6-cyclopentyl-9-[(3-methoxyphenyl)amino]-2-methyl-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-3-one 6-cyclopentyl-9-[(2-methoxyphenyl)amino]-2-methyl-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-3-one tert-butyl 8,10-dibromo-7-oxo-1,2,5,5a,6,7-hexahydro-[1,4]diazepino[1,7-a]quinazoline-3(4H)-carboxylate tert-butyl 8,10-dimethyl-7-oxo-1,2,5,5a,6,7-hexahydro-[1,4]diazepino[1,7-a]quinazoline-3(4H)-carboxylate 11-Diallylaminoacetyl-6-isopropyl-5,6-dihydropyrimido[4,5-b][1,5]benzodiazepin-5-one 6-butyl-11-diallylaminoacetyl-2-phenyl-5,6-dihydropyrimido[4,5-b][1,5]benzodiazepin-5-one 11-chloroacetyl-6-isopropyl-5,6-dihydropyrimido[4,5-b][1,5]benzodiazepin-5-one 4-[(2-cyclopentyl-4,4,6-trimethyl-5-oxo-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-10-yl)amino]benzoic acid 4-[(2-cyclopentyl-6-methyl-5-oxo-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-10-yl)amino]-3-methoxy-N-(4-piperidyl)benzamide 4-[(6-cyclopentyl-2-methyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl)amino]-N-(1-ethyl-4-piperidyl)-3-methoxy-benzamide 8-(4-chlorophenyl)-6-phenyl-9H-pyrimido[4,5-b][1,4]diazepin-4-ol 1-chloro-7-methoxy-8-(3-morpholin-4-yl-propoxy)-10,11-dihydro-5H-2,4,5,11-tetraaza-dibenzo[a,d]cycloheptene 4-[(6-cyclopentyl-2-methyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl)amino]-3-methoxy-N-methyl-benzamide (S)-tert-butyl (4-chloro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-7-yl)carbamate 3-methoxy-4-[[6-(2-methoxyethyl)-2-methyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl]amino]-N-(1-methyl-4-piperidyl)benzamide (9aS,9R)-4-chloro-N-(4-methylphenyl)-9a,10,11,12-tetrahydro-9H-pyrimido[4,5-b]dipyrrolo[1,2-d:2',1'-g][1,4]diazepin-9-amine